Autres langues OmniAb, Inc.

Actions

OABI

US68218J1034

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/05/2024			Varia. 5j.	Varia. 1 janv.
4,68 ^USD	+2,41%		+0,21%	-24,15%

09/05	Transcript : OmniAb, Inc., Q1 2024 Earnings Call, May 09, 2024
25/03	Un initié d'OmniAb a acheté des actions pour une valeur de 1 167 750 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Earnings Flash (OABI) OMNIAB Reports Q1 Revenue $3.8M, vs. Street Est of $5.9M	09/05
OmniAb Reports First Quarter 2024 Financial Results and Business Highlights	09/05
OmniAb to Participate in Five Investor Conferences in May	01/05
OmniAb to Report First Quarter 2024 Financial Results on May 9	22/04
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate Biotherapeutics	16/04
OmniAb : March 2024 Corporate Overview	26/03
OmniAb Insider Bought Shares Worth $1,167,750, According to a Recent SEC Filing	25/03
Sector Update: Health Care Stocks Gain Pre-Bell Thursday	21/03
OmniAb Swings to Q4 Loss, Revenue Declines	20/03
Earnings Flash (OABI) OMNIAB Posts Q4 Revenue $4.8M, vs. Street Est of $7.46M	20/03
OmniAb, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	20/03
OmniAb to Report Fourth Quarter 2023 Financial Results on March 20	26/02
OmniAb to Participate in Two Investor Conferences in March	20/02
OmniAb, Inc.(NasdaqGM:OABI) added to NASDAQ Biotechnology Index	18/12
OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering and Therapeutics Conference	15/12
OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference	14/12
OmniAb, Inc. Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference	14/12
Omniab Insider Bought Shares Worth $1,010,000, According to a Recent SEC Filing	13/12
Omniab Insider Bought Shares Worth $405,517, According to a Recent SEC Filing	13/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues OmniAb, Inc.

Actions

OABI

US68218J1034

Autres langues

Filtres